The bill amends the Controlled Substance, Drug, Device and Cosmetic Act to include tianeptine as a controlled substance under Schedule II, which indicates it has a high potential for abuse and may lead to severe dependence. Specifically, the bill adds tianeptine to the list of substances in Schedule II, alongside other narcotics such as hydrocodone and oxycodone. This inclusion aims to regulate the manufacture, sale, and possession of tianeptine, reflecting growing concerns about its potential for abuse and adverse health effects.

Additionally, the bill establishes a new section that mandates the Department of Health to monitor adverse health events related to tianeptine. This includes collecting data from various health and law enforcement agencies and issuing public advisories when necessary. The Department is also empowered to create rules and regulations for reporting and data collection regarding tianeptine-related health issues, which encompass a range of physical and psychological symptoms, as well as any emergency medical interventions linked to its use. The act is set to take effect 60 days after its passage.

Statutes/Laws affected:
Printer's No. 1067 (Jul 23, 2025): P.L.233, No.64